Sage Therapeutics (SAGE) and Biogen (BIIB) announced that the U.S. FDA notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SAGE: